Lennartz, Simon
Mager, Alina
Große Hokamp, Nils
Schäfer, Sebastian
Zopfs, David
Maintz, David
Reinhardt, Hans Christian
Thomas, Roman K.
Caldeira, Liliana
Persigehl, Thorsten
Funding for this research was provided by:
Else Kröner-Fresenius-Stiftung (2016-Kolleg-19)
Else Kröner-Fresenius-Stiftung (2018_EKMS.34)
Article History
Received: 29 January 2020
Accepted: 18 December 2020
First Online: 26 January 2021
Ethics approval and consent to participate
: This study was approved by the Institutional Review Board and informed consent was waived due to the retrospective character of the study.
: Not applicable.
: The authors of this manuscript declare relationships with the following companies: Simon Lennartz: received research support from Philips. Nils Große Hokamp: received talk honoraria and research support from Philips. David Maintz: received talk honoraria from Philips. Sebastian Schäfer: is an employee of Mint Medical GmbH. Hans Christian Reinhardt: received consulting and lecture fees from Abbvie, Astra-Zeneca, Vertex and Merck, as well as research funding from Gilead Pharmaceuticals. Roman Thomas: founder of NEO New Oncology.